Protein signatures to distinguish aggressive from indolent prostate cancer.

ABSTRACT:

Background

Distinguishing men with aggressive from indolent prostate cancer is critical to decisions in the management of clinically localized prostate cancer. Molecular signatures of aggressive disease could help men overcome this major clinical challenge by reducing unnecessary treatment and allowing more appropriate treatment of aggressive disease.

Methods

We performed a mass spectrometry-based proteomic analysis of normal and malignant prostate tissues from 22 men who underwent surgery for prostate cancer. Prostate cancer samples included Grade Groups (3-5), with 8 patients experiencing recurrence and 14 without evidence of recurrence with a mean of 6.8 years of follow-up. To better understand the biological pathways underlying prostate cancer aggressiveness, we performe

SUBMITTER: Garcia-Marques F 

PROVIDER: S-EPMC8916040 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature